ArticleOncotarget2026
Systematic methodological flaws in DNA contamination assessment of mRNA vaccines: A critical analysis of Achs et al. (2025).
Article in Oncotarget, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copyright: © 2026 McKernan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Recent work by Achs et al. (2025) claimed to demonstrate no excessive residual DNA in COVID-19 mRNA vaccines using four orthogonal approaches. Since this work is being cited by regulatory authorities to claim DNA levels in mRNA vaccines are within limits, it is imperative that a robust public discussion occur regarding the methods strengths and weaknesses. We present a comprehensive critique identifying critical methodological flaws that systematically bias results toward underestimation of residual DNA contamination. These include: (1) inappropriate plasmid molecular weight calculations producing 1.5–10× underestimation (plasmid equivalents), (2) fragment size bias in primer design favoring detection of non-functional sequences over spike-encoding DNA, (3) thermal degradation of samples during library preparation, (4) analytical detection limits exceeding regulatory thresholds, (5) platform limitations excluding detection of kilobase-length DNA fragments, and (6) failure to account for RNA:DNA hybrid formation protecting spike DNA from degradation. Collectively, these flaws render the study's conclusions invalid for regulatory assessment of residual DNA contamination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.